Membrane-bound alkaline phosphatase gene induces antitumor effect by G2/M arrest in etoposide phosphate-treated cancer cells

Molecular and Cellular Biochemistry

Volumn 252, Issue 1-2, 2003, Pages 213-221

  Kim, Kye Young ^a,d   Cho, Young Joo ^a   Jeon, Geoung A ^b   Ryu, Pan Dong ^c   Nam, Myeong Jin ^a  

^a Korea National Institute of Health   (South Korea)

^b Research Institute of Molecular Genetics   (South Korea)

^c Seoul National University   (South Korea)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Alkaline phosphatase; Antitumor activity; Etoposide; Etoposide phosphate; Gene therapy; Prodrug converting system

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; COMPLEMENTARY DNA; DIMETHYL SULFOXIDE; DNA FRAGMENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOFOS; ETOPOSIDE; GENOMIC DNA; INTESTINE ENZYME; MEMBRANE ENZYME; PRODRUG; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL POPULATION; CHROMOSOME ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIZATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; GENETIC TRANSDUCTION; GENOME ANALYSIS; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; SIDE EFFECT; STOMACH CANCER; SUBCUTANEOUS TISSUE TUMOR; TREATMENT PLANNING; TUMOR CELL; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ALKALINE PHOSPHATASE; ANIMALS; CELL MEMBRANE; ETOPOSIDE; FLOW CYTOMETRY; G2 PHASE; MICE; MICE, INBRED BALB C; MITOSIS; ORGANOPHOSPHORUS COMPOUNDS; POLYMERASE CHAIN REACTION; RATS;

ANIMALIA; MUS MUSCULUS; UNIDENTIFIED RETROVIRUS;

EID: 0141616545     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025572815125     Document Type: Article

References (42)

1. Mullen CA, Kilsrtup M, Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system. Proc Natl Acad Sci USA 89: 33-37, 1992
2. Ezzeddine ZD, Martuza RL, Platika D, Short MP, Malick AB, Breakefield XO: Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex-thymidine kinase gene. New Biol 3: 608-614, 1991
3. Elshami AA, Kucharczuk JC, Zhang HB, Smythe WR, Hwang HC, Litzky LA, Kaiser LR, Albelda SM: Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 7: 141-148, 1996
4. Lowe M, Strauss AW, Alpers R, Seetharam S, Alpers DH: Molecular cloning and expression of a cDNA encoding the membrane-bound-associated rat intestinal alkaline phosphatase. Biochim Biophys Acta 1037: 170-177, 1990
5. Senter PD, Schreiber GJ, Hirschberg DL, Ashe SA, Hellstrom KE, Hellstrom I. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res 49: 5789-5792, 1989
6. Senter PD, Saulnier MG, Schreiber GJ, Hirschberg DL, Brown JP, Hellstrom I, Hellstrom KE: Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 85: 4842-4846, 1988
7. Edwards DC: Targeting potential of antibody conjugates. Pharmacol Ther 23: 147-177, 1983
8. Thorpe PE: Antibody carriers of cytotoxic agents in cancer therapy: A review. In: A. Pinchera, G. Doria, F. Dammacco, A. Bargellesi (eds). Monoclonal Antobodies '84: Biological and Clinical Applications. Editrice Kurtis s.r.l., Milan, Italy, 1985, pp 475-506
9. Vallera DA, Ash RC, Zanjani ED, Kersey JH, Lebien TW, Beverley PC, Neville DM Jr, Youle RJ: Anti-T cell reagents for human bone marrow transplantation: Ricin linked to three monoclonal antibodies. Science 222: 512-515, 1983
10. Jain RK, Baxter LT: Mechanisms of heterogenous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 48: 7022-7032, 1988
11. Kay M, Woo S: Gene therapy for metabolic disorders. Trends Genes 10: 253-257, 1994
12. Crystal RG: Transfer genes to humans: Early lesions and obstacles to success. Science 270: 404-410, 1995
13. Engle MJ, Mahmood A, Alpers DH: Two rat intestinal alkaline phosphatase isoforms with different carboxyl-terminal peptides are both membrane-bound by a glycan phosphatidylinositol linkage. J Biol Chem 270: 11935-11940, 1995
14. Berger J, Garattini E, Hua JC, Udenfriend S: Cloning and sequencing of human intestinal alkaline phosphatase cDNA. Proc Natl Acad Sci USA 84: 95-698, 1987
15. Fishman WH: Perspectives on alkaline phosphatase isoenzymes. Am J Med 56: 617-650, 1974
16. Huber BE, Richards CA, Krenitsky TA: Retroviral-mediated gene therapy for the treatment of the hepatocellular carcinoma: An innovative approach for cancer therapy. Proc Natl Acad Sci USA 88: 8039-8043, 1991
17. Belani CP, Doyle LA, Aisner J: Etoposide: Current status and future perspectives in the management of malignant neoplasms. Cancer Chemother Pharmacol 34: S118-S126, 1994
18. DeVore R, Hainsworth J, Greco FA, Hande K, Johnson D: Chronic oral etoposide in the treatment of lung cancer. Semin Oncol 19: 28-35, 1992
19. Kaufmann SH: Cell death induced by topoisomerase-targeted drugs: More questions than answers. Biochim Biophys Acta 1400: 195-211, 1998
20. Lock RB: Inhibition of p34cdc2 kinase activation, p34cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide. Cancer Res 52: 1817-1822, 1992
21. Nitiss JL, Liu YX, Hsiung Y: A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: A genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res 53: 89-93, 1993
22. Burden DA, Kingma PS, Froelich-Ammon SJ, Bjornsti MA, Patchan MW, Thompson RB, Osherohh N: Topoisomerase II-etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J Biol Chem 271: 29238-29244, 1996
23. Osheroff N: Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: Inhibition of DNA religation by emposide. Biochemistry 28: 6157-6160, 1989
24. Hande KR: Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34: 1514-1521, 1998
25. Hainsworth JD, Levitan N, Wampler GL, Belani CP, Seyedsadr MS, Randolph J, Schacter LP, Greco FA: Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer. J Clin Oncol 13: 1436-1442, 1995
26. Lose WK, Basler GA, Trail PA: Preclinical antitumor activity of a soluble etoposide analog, BMY-40481. Invest New Drug 8: 525-532, 1990
27. Park JG, Yang HK, Kim WH, Chung JK, Kang MS, Lee JH, Oh JH, Park HS, Yeo KS, Kang SH, Song SY, Kang YK, Bang YJ, Kim YI, Kim JP: Establishment and characterization of human gastric carcinoma cell lines. Int J Cancer 70: 443-449, 1997
28. Mulivor RA, Hannig VL, Harris H: Developmental change in human intestinal alkaline phosphatase. Proc Natl Acad Sci USA 75: 3909-3912, 1978
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951
30. Carmichael J, Degraff WG, Gazdar AF, Minna JD, Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987
31. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Meth 65: 55-62, 1983
32. Kuriyama S, Nakatani T, Masui K, Sakamoto T, Tominaga K, Yoshikawa M, Fukui H, Ikenaka K, Tsujii T: Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology 22: 1838-1846, 1995
33. Hwang BD, Weon SA, Kweon GR, Kim KY, Kang DY, Kwak ST, Lim, K: Studies on expression of DNA topoisomerases genes and proto-oncogene c-myc during hepatocarcinogenesis. J Korean Cancer Assoc 25: 636-650, 1993
34. Liu LF, Rowe TC, Yang L, Teway KM, Chen GL: Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258: 15365-15370, 1983
35. Drlica K, Franco RJ: Inhibitors of DNA topoisomerase. Biochemistry 27: 2253-2259, 1988
36. Wang JC: Recent studies of DNA topoisomerases. Biochem Biophys Acta 909: 1-9, 1987
37. O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE: Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med 312: 692-700, 1985
38. Wang X, Pang L, Feng J: A phase II study of etoposide, doxorubicin, and carboplatin in the treatment of advanced gastric cancer. Am J Clin Oncol 25: 71-75, 2002
39. Shigemitsu K, Naomoto Y, Matsuno T, Gochi A, Isozaki H: Advanced gastric cancer with multiple lymph node metastasis successfully treated with etoposide, adriamycin and cisplatin. J Gastroenterol Hepatol 16: 581-585, 2001
40. Haller J, Burgess R, Dawson P: Increased cytotoxicity of squamous cell carcinoma of the head and neck by combining cisplatin-with VP-16 and ciprofloxacin. Larygoscope 103: 1081, 1083, 1993
41. Bruzzone R, Meda P: The gap junction: A channel for multiple functions? Eur J Clin Invest 18: 444-453, 1988
42. Subak-Sharpe H, Burk RR, Pitts JD: Metabolic co-operation between biochemically marked mammalian cells in tissue culture. J Cell Sci 4: 353-367, 1969